Agreement on Exclusive Distributorship for Sales of Johnson & Johnson's Non-prescription Drugs in Japan

Main contents starts here

Press Releases

August 3, 2012

Takeda Pharmaceutical Company Limited

Agreement on Exclusive Distributorship
for Sales of Johnson & Johnson's Non-prescription Drugs in Japan

Osaka, Japan, August 3, 2012—Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it has signed an agreement (“the Agreement”) with Johnson & Johnson K. K. Consumer Company ("Johnson & Johnson") for the exclusive distribution right in Japan of seven OTC brands* currently marketed by Johnson & Johnson. Between Takeda and Johnson & Johnson, there already exists an agreement under which Takeda holds the exclusive distribution right in Japan of Nicorette^®, a non-prescription (OTC) smoking cessation aid. Both parties will prepare for the transition, and Takeda plans to start its sales and promotional activities of the said seven OTC brands by the end of calendar year 2012.

*Seven OTC brands: Aneton^®, antitussive/expectorant and treatment rhinitis; Tylenol^®, antipyretic/analgesic; COR-TYZINE^®, rhinitis rtreatment; Visine^®, eye drops; and Terres^® Hi, Terra-Cortril^®, and Terramycin^®, dermatological preparations

Based on the Agreement, Takeda will strengthen its existing categories of cold remedies and eye drops, and obtain the new category of dermatological treatments. The enhanced product lineups will allow Takeda to enhance its presence in the OTC drug market, which is expected to grow toward the future in line with the increased health consciousness among Japanese people.

“I am very much pleased that we are able to handle Johnson & Johnson's OTC products in Japan. With the widely spreading consciousness of self-medication in Japan, the additions of a larger variety of OTC products will further encourage our determination to contribute to the good health of Japanese people,” said Masashi Sugimoto, President of Takeda's Consumer Healthcare Company.

There will be no upfront payment in connection with the Agreement, and there is no modification to Takeda’s consolidated earnings forecasts for fiscal 2012.

###

Skip sub navigation